Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): A time-series and benchmarking study

BMJ Open

Volumn 4, Issue 10, 2014, Pages

  Sarayani, Amir ^a   Rashidian, Arash ^b,c   Gholami, Kheirollah ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; PIG INSULIN; PIOGLITAZONE; REPAGLINIDE;

AFFORDABILITY; ARTICLE; DIABETES MELLITUS; DRUG COST; DRUG UTILIZATION; QUALITY CONTROL; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; TREATMENT DURATION; DEVELOPING COUNTRY; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE DELIVERY; HUMAN; IRAN; TRENDS;

BENCHMARKING; DEVELOPING COUNTRIES; DIABETES MELLITUS; DRUG COSTS; DRUG UTILIZATION; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPOGLYCEMIC AGENTS; INTERRUPTED TIME SERIES ANALYSIS; IRAN; RETROSPECTIVE STUDIES;

EID: 84908037589     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005859     Document Type: Article

References (41)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
2. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
3. Alldredge BK, Corelli RL, Ernst ME, et al. Koda-Kimble & Young's applied therapeutics; the clinical use of drug. 10th edn. Lippincott Williams & Wilkins, 2012.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
5. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
6. Melander A, Folino-Gallo P, Walley T, et al. Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia 2006;49:2024-9.
7. Doró P, Benko R, Kosik E, et al. Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur J Clin Pharmacol 2005;61:893-7.
8. Baviera M, Monesi L, Marzona I, et al. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy region: a large population-based study. Diabetes Res Clin Pract 2011;93:123-30.
9. Rashidian A, Jahanmehr N, Jabbour S, et al. Bibliographic review of research publications on access to and use of medicines in low-income and middle-income countries in the Eastern Mediterranean Region: identifying the research gaps. BMJ Open 2013;3:e003332.
10. Esteghamati A, Meysamie A, Khalilzadeh O, et al. Third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health 2009;9:167.
11. Esteghamati A, Gouya MM, Abbasi M, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes Care 2008;31:96-8.
12. Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, et al. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J 2009;15:591-9.
13. Oliaimanesh A, Abolhallaj M, Zangeneh M, et al. National Health Accounts Islamic Republic of Iran-2008. Tehran: National Institue of Health Research, Ministry of Health and Medical Education, 2013.
14. Rashidian A, Khosravi A, Khabiri R, et al. Islamic Republic of Iran's Multiple Indicator Demographic and Health Survey (IrMIDHS)-2010. Tehran: National Institue of Health Research, Ministry of Health and Medical Education, 2012.
15. Davari M, Haycox A, Walley T. The Iranian Health Insurance System; past experiences, present challenges and future strategies. Iranian J Public Health 2012;41:1-9.
16. Kavosi Z, Rashidian A, Pourreza A, et al. Inequality in household catastrophic health care expenditure in a low-income society of Iran. Health Policy Plan 2012;27:613-23.
17. Cheraghali AM, Nikfar S, Behmanesh Y, et al. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran. East Mediterr Health J 2004;10:406-15.
18. Abdollahiasl A. Medicine prices, availability, affordability and price components-Iran. Medicine prices and access to medicines in the Eastern Mediterranean Region. Cairo, Egypt: Essential Medicines and Pharmaceutical Policies Unit, World Health Organization, Regional Office for the Eastern Mediterranean, 2010.
19. Dinarvand R. New National Drug Policy in Iran leading to expanded pharmaceutical market and extended access of public to medicines. Iran J Public Health 2009;38(Suppl 1):158-61.
20. Davari M, Walley T, Haycox A. Pharmaceutical Policy and Market in Iran: past experiences and future challenges. J Pharm Health Serv Res 2011;2:47-52.
21. Iran Pharmaceuticals & Healthcare Report Q2. London, UK: Business Monitor International, 2009.
22. OECD. OECD Health Data: Pharmaceutical market. http://dx.doi.org/10.1787/data-00545-en
23. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2013. Oslo, 2012. www.whocc.no/filearchive/publications/1-2013guidelines.pdf
24. Wettermark B, Pehrsson Å, Jinnerot D, et al. Drug utilisation 90% profiles - a useful tool for quality assessment of prescribing in primary health care in Stockholm. Pharmacoepidemiol Drug Saf 2003;12:499-510.
25. WHO Model List of Essential Medicines. World Health Organization, 2013. http://www.who.int/medicines/publications/essentialmedicines/18th-EML-Final-web-8Jul13.pdf
26. International Diabetes Federation-DIABETES ATLAS UPDATE 2012. http://www.idf.org/diabetesatlas/5e/Update2012
27. Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009;373:240-9.
28. Esteghamati A, Ashraf H, Khalilzadeh O, et al. Trends of diabetes according to body mass index levels in Iran: results of the national Surveys of Risk Factors of Non-Communicable Diseases (1999-2007). Diabet Med 2010;27:1233-40.
29. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998:703-13.
30. Peimani M, Tabatabaei-Malazy O, Heshmat R, et al. Knowledge, attitude and practice of physicians in the field of diabetes and its complications: a pilot study. Iran J Diabetes Lipid Disord 2010;9:1-7.
31. Shakibazadeh E, Larijani B, Shojaeezadeh D, et al. Patients' perspectives on factors that influence diabetes self-care. Iran J Public Health 2011;40:146-58.
32. Mounesan L, Nedjat S, Majdzadeh R, et al. Only one third of Tehran's physicians are familiar with 'Evidence-Based Clinical Guidelines'. Int J Prev Med 2013;4:349-57.
33. Sarayani A, Rashidian A, Gholami K, et al. Efficacy of continuing education in improving pharmacists' competencies for providing weight management service: three-arm randomized controlled trial. J Contin Educ Health Prof 2012;32:163-73.
34. Forsetlund L, Bjørndal A, Rashidian A, et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2009;(2): CD003030.
35. Beran D, McCabe A, Yudkin JS. Access to medicines versus access to treatment: the case of type 1 diabetes. Bull World Health Organ 2008;86:648-9.
36. Beran D, Yudkin JS. Looking beyond the issue of access to insulin: what is needed for proper diabetes care in resource poor settings. Diabetes Res Clin Pract 2010;88:217-21.
37. Cheraghali AM. Impacts of international sanctions on Iranian pharmaceutical market. Daru 2013;21:64.
38. Butler D. Iran hit by drug shortage. Nature 2013; 504:15-16.
39. OECD Health Data 2013 Definitions, Sources and Methods: Pharmaceutical consumption by DDDs: OECD Health Data. 2013. http://www.oecd.org/health/healthdata
40. Sarayani A, Jahangard-Rafsanjani Z, Hadjibabaie M, et al. A comprehensive review of adherence to diabetes and cardiovascular medications in Iran; implications for practice and research. J Diabetes Metab Disord2013;12:57.
41. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24.